AbbVie said the European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. This regulatory approval supports commercialization prospects for an oncology combination therapy. The update is likely incremental for AbbVie but positive for sentiment toward its hematology pipeline.
AbbVie said the European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. This regulatory approval supports commercialization prospects for an oncology combination therapy. The update is likely incremental for AbbVie but positive for sentiment toward its hematology pipeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
